You Can't Negotiate What You Don't Understand: Red Teaming and the Future of AI Contract Architecture

There's a moment in every healthcare AI deployment conversation when someone in the room says some version of: "

We'll monitor it post-launch and course-correct as needed."

It's a reasonable-sounding sentence. It's also one of the most dangerous things you can say when the product in question is making recommendations that influence patient care.

The post-launch feedback loop in healthcare doesn't look like a product bug report. It looks like an adverse event. A delayed diagnosis. A care team that trusted an AI summary that quietly omitted a critical contraindication. By the time you've "course-corrected," you may have already lost something you can't get back — patient safety, institutional trust, or both.

This is why red teaming is no longer optional for healthcare AI. It's a prerequisite.

What Red Teaming Actually Means in This Context

Red teaming, borrowed from national security and cybersecurity, is the practice of systematically attacking your own system before an adversary — or reality — does it for you. In the context of healthcare AI, it means assembling a team whose explicit job is to find every way your model can fail, mislead, hallucinate, be manipulated, or cause harm — before any of that happens in a live clinical environment.

This isn't just about technical robustness. Healthcare AI red teaming spans at least four interconnected risk domains:

• Clinical safety: Does the model produce outputs that could lead to incorrect diagnoses, inappropriate treatment recommendations, or missed contraindications? Does it perform differently across patient subpopulations in ways that could deepen health disparities? What happens when it encounters atypical presentations, rare diseases, or ambiguous labs?

  
  

• Adversarial manipulation: Can a bad actor — or even an uninformed but persistent user — use prompt injection to override safety guardrails? Can they extract protected health information through carefully crafted queries? Can they cause a retrieval-augmented generation (RAG) system to surface false or misleading source material by manipulating what's in the knowledge base?

  
  

• Operational brittleness: What happens when the model encounters data that looks nothing like its training distribution — a non-standard EHR format, a note written by a non-native English speaker, a pediatric patient in a model trained on adult data? Does it fail loudly or quietly? Quiet failures are almost always more dangerous.

  
  

• Systemic trust calibration: Does the model communicate uncertainty accurately? Is it designed to foster appropriate clinical skepticism, or does its interface inadvertently encourage over-reliance? A model that is right 93% of the time but presents all outputs with equal confidence is a model optimized to cause harm in that remaining 7%.

The Legal Layer Nobody Is Talking About Enough

Red teaming has one more critical function that is, frankly, underappreciated in most AI deployment conversations: it generates the evidentiary foundation for sound contract architecture.

Understanding actual AI failure modes — prompt injection, data exfiltration, RAG behavior, and associated risk profiles — directly enables legal teams to craft more meaningful representations and warranties, risk allocations, covenant structures, and indemnification provisions. The insight is important enough to say plainly: you cannot negotiate AI contracts intelligently without first knowing how the system fails.

Health enterprises signing AI vendor agreements right now are, in most cases, doing so without this knowledge. They are accepting risk allocations written by parties with far more information about the model's failure modes than they have. That asymmetry has consequences.

Red teaming outputs could feed directly into the contracting process in ways the industry hasn't fully explored yet. Consider what becomes possible:

Representations and warranties could be grounded in tested performance bounds rather than marketing language. If red teaming surfaces that a model degrades significantly on certain patient subpopulations, or can be manipulated into generating erroneous prescription recommendations, that's a warranty scope issue — one a health system could negotiate around explicitly rather than discover post-deployment.

Risk allocation could reflect demonstrated failure modes rather than generic boilerplate. An agentic system capable of writing or modifying cardiovascular prescriptions carries specific adversarial risk profiles: prompt injection attacks designed to alter dosing logic, adversarial inputs that exploit edge cases in drug interaction reasoning, or RAG knowledge base manipulation that surfaces outdated or incorrect clinical guidance. A vendor that knows their system is susceptible to these vectors could be holding more of that risk contractually. But you can only negotiate for that if you know the vulnerability exists.

Indemnification structures could account for the meaningful difference between general negligence and AI-specific failure patterns. Standard malpractice indemnification frameworks were not designed with hallucination risk, prescription manipulation, or agentic overstep in mind. As clinical AI systems gain the ability to autonomously act — not just advise — those distinctions become legally material in ways courts haven't yet fully adjudicated.

Covenants — the ongoing operational obligations in a contract — could include red teaming cadence requirements, incident reporting protocols for model drift, and defined testing standards before any model update reaches a production environment. These provisions only become enforceable once both parties understand what they're testing for.

None of this is settled law or standard practice yet. That's precisely the point. The health enterprises and vendors that develop this vocabulary now — grounded in real adversarial test results rather than theoretical risk categories — could find themselves with significantly stronger contractual positions as the regulatory and litigation environment matures around them.

The legal layer of healthcare AI is still catching up to the technical reality. Red teaming is how you begin to close that gap before you sign anything.

What a Healthcare Red Team Actually Looks Like

Effective red teaming for clinical AI isn't a one-day penetration test. It's a structured, multi-disciplinary process that typically includes:

• Clinical domain experts — physicians, nurses, pharmacists, and specialists who can recognize failure modes that technical testers would never catch. They bring the clinical intuition to ask: "What would a fatigued hospitalist do with this output at 2am?"

  
  

• Adversarial AI specialists — researchers with deep experience in prompt injection, jailbreaking, model extraction, and knowledge base manipulation. The clinical team doesn't know these attack vectors; the red team does.

  
  

• Health equity reviewers — focused specifically on differential model performance across race, ethnicity, age, language, socioeconomic status, and other dimensions of patient identity. Bias in healthcare AI doesn't announce itself. You have to look for it.

  
  

• Regulatory and compliance counsel — who can map identified vulnerabilities to specific liability exposures under HIPAA, FDA guidance on AI/ML-based SaMD, and emerging state-level AI regulations.

  
  

• Downstream workflow analysts — because a model that performs adequately in isolation may still cause harm when integrated into a specific clinical workflow. The interface, the alert design, the default trust posture of the users — all of these shape the real-world risk profile.

The ROI Framing That Actually Resonates

There's a tendency to position red teaming as a cost — as friction added to deployment timelines. That framing gets the economics exactly backwards.

The true cost calculation looks like this: the cost of red teaming is bounded and known. The cost of a clinical adverse event, a regulatory enforcement action, a headline, or a class action is none of those things. Health systems that have lived through institutional trust crises understand that recovery is measured in years and sometimes isn't achievable at all.

Red teaming also generates direct enterprise value beyond risk avoidance:

It creates the documented evidence base that regulators, accreditors, and health system boards increasingly expect to see before approving AI deployments.

It accelerates procurement cycles by giving enterprise buyers the third-party validation they need to move through governance committees.

It produces the technical specificity that enables meaningful vendor differentiation — because "our model is safe and accurate" is a claim every vendor makes, and "here is our red team report" is a claim almost none of them can make.

The Standard Is Being Set Now

Healthcare AI is at an inflection point. The systems being deployed today, and the contracts being signed today, will define the risk architecture of the industry for the next decade. ARPA-H's ADVOCATE program — with its supervisory agent, FDA authorization pathway, and explicit mandate for continuous safety monitoring — is a preview of where federal standards are heading. The organizations that build rigorous pre-deployment adversarial testing infrastructure now will not be playing catch-up when those standards arrive. They will have built the foundation already.

That's not just a safety position. It's a strategic one.

At ALIGNMT AI, we believe that responsible deployment and commercial success are not in tension — that the organizations building the most trustworthy AI infrastructure will also build the most durable competitive positions. Red teaming is foundational to both.

The question isn't whether your AI will encounter edge cases, adversarial inputs, or unexpected failure modes in the real world. It will. The question is whether you found them first.